Overview
- Missouri Attorney General Catherine Hanaway filed the expanded complaint with Kansas and Idaho targeting the FDA’s Sept. 30 approval of Evita Solutions’ generic mifepristone.
- The states ask the Eastern District of Missouri to void the Evita approval, reinstate pre-2016 safeguards such as in‑person exams, and bar mailing of the pills.
- The lawsuit, transferred from Texas, is now before U.S. District Judge Cristian Stevens in St. Louis with no rulings or hearing dates announced.
- State filings argue loosened rules increased risks and cite emergency-room visit data, while FDA materials note rare serious complications across millions of uses.
- The FDA and Evita did not respond to requests for comment, and HHS Secretary Robert F. Kennedy Jr. has said generics must be approved when shown identical to the brand.